$Impaired active relaxation during dynamic exercise in patients with heart failure with a preserved ejection fraction (HfpEF)$

Impaired active relaxation during dynamic exercise in patients with heart failure with a preserved ejection fraction (HfpEF)

Podrobná bibliografie
Hlavní autoři:	Phan, T, Nallur-Shivu, G, Abozguia, K, Mahadevan, G, Ahmed, I, Anderson, S, Williams, L, Nassimizadeh, M, Clarke, K, Frenneaux, M
Médium:	Journal article
Vydáno:	2008

Podobné jednotky

Tubulin expression and modification in heart failure with preserved ejection fraction (HFpEF)
Autor: Lisa Schulz, a další
Vydáno: (2022-09-01)

Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF)
Autor: María Valero-Muñoz, a další
Vydáno: (2022-08-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): A Case Report
Autor: Amanda Halimi, a další
Vydáno: (2021-09-01)

Features of heart failure with preserved ejection fraction (HFpEF) in diabetic patients with resistant hypertension
Autor: M. A. Manukyan, a další
Vydáno: (2021-11-01)

Impact of readmissions on octogenarians with heart failure with preserved ejection fraction: PURSUIT‐HFpEF registry
Autor: Masami Nishino, a další
Vydáno: (2021-06-01)

Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency.
Autor: Phan, T, a další
Vydáno: (2009)

Focus on HFpEF in heart failure
Autor: Chunhui He, a další
Vydáno: (2022-05-01)

Predictors and Mortality for Worsening Left Ventricular Ejection Fraction in Patients With HFpEF
Autor: Liling Chen, a další
Vydáno: (2022-02-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): Part 3 Devices Based Treatment and Commentary
Autor: Soneil Guptha , Eteri Tsetskhladze
Vydáno: (2024-08-01)

Enhanced central sympathetic tone induces heart failure with preserved ejection fraction (HFpEF) in rats
Autor: Shyam S. Nandi, a další
Vydáno: (2023-12-01)

Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA‐HFpEF trial
Autor: Mariëlle Scheffer, a další
Vydáno: (2020-12-01)

Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations
Autor: Dzhioeva O, a další
Vydáno: (2020-08-01)

The gut microbiota-inflammation-HFpEF axis: deciphering the role of gut microbiota dysregulation in the pathogenesis and management of HFpEF
Autor: Shenghua Zhou, a další
Vydáno: (2025-03-01)

Heart failure with preserved ejection fraction (HFpEF) pathophysiology study (IDENTIFY-HF): does increased arterial stiffness associate with HFpEF, in addition to ageing and vascular effects of comorbidities? Rationale and design
Autor: Prithwish Banerjee, a další
Vydáno: (2019-11-01)

The Oxygen Cascade According to HFpEF Likelihood
Autor: Jan Verwerft, MD, a další
Vydáno: (2024-07-01)

Carnitine is a friend in HFpEF and foe in HFrEF
Autor: Huiqing Wang, a další
Vydáno: (2024-10-01)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
Autor: Norman Mangner, a další
Vydáno: (2023-10-01)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
Autor: Leonie Grossekettler, a další
Vydáno: (2020-05-01)

Arterial Stiffness Is an Important Predictor of Heart Failure with Preserved Ejection Fraction (HFpEF)—The Effects of Phosphate Retention
Autor: Yuji Mizuno, a další
Vydáno: (2024-05-01)

Accelerometer vs. other activity measures in heart failure with preserved ejection fraction: the VITALITY‐HFpEF trial
Autor: Javed Butler, a další
Vydáno: (2024-02-01)

Loeffler Endocarditis Causing Heart Failure with Preserved Ejection Fraction (HFpEF): Characteristic Images and Diagnostic Pathway
Autor: Silvia Lupu, a další
Vydáno: (2022-09-01)

Diabetes Is the Strongest Predictor of Limited Exercise Capacity in Chronic Heart Failure and Preserved Ejection Fraction (HFpEF)
Autor: Venera Berisha-Muharremi, a další
Vydáno: (2022-05-01)

Editorial: HFpEF and HFmrEF: Different Sides of the Same Coin?
Autor: Manuel Martínez-Sellés, a další
Vydáno: (2022-05-01)

Different determinants of exercise capacity in HFpEF compared to HFrEF
Autor: Arlind Batalli, a další
Vydáno: (2017-04-01)

Prognostic significance of dipstick proteinuria in heart failure with preserved ejection fraction: insight from the PURSUIT-HFpEF registry
Autor: Tetsuhisa Kitamura, a další
Vydáno: (2021-09-01)

Application Value of Systemic Inflammatory Indexes in the Clinical Evaluation of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)
Autor: Ruxin Wang, a další
Vydáno: (2022-10-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): Part 1 Review of Experience and Evidence in PARAGON-HF with Commentary
Autor: Soneil Guptha; Eteri Tsetskhladze
Vydáno: (2023-07-01)

Predictive potential of macrophage migration inhibitory factor (MIF) in patients with heart failure with preserved ejection fraction (HFpEF)
Autor: Peter Luedike, a další
Vydáno: (2018-05-01)

Epicardial adipose tissue and exercise intolerance in HFpEF
Autor: Michelle Lobeek, a další
Vydáno: (2024-10-01)

HFpEF as systemic disease, insight from a diagnostic prediction model reminiscent of systemic inflammation and organ interaction in HFpEF patients
Autor: Rong Zhou, a další
Vydáno: (2024-03-01)

Characteristics, prognosis, and treatment response in HFpEF patients with high vs. normal ejection fraction
Autor: Jun Gu, a další
Vydáno: (2022-09-01)

Hemodynamic force assessment by cardiovascular magnetic resonance in HFpEF: A case-control substudy from the HFpEF stress trialResearch in context
Autor: Sören J. Backhaus, a další
Vydáno: (2022-12-01)

Prevalence of Prediabetes and Newly diagnosed Diabetes in Patients with HFpEF and HFrEF
Autor: Ahmad ELSharawy, a další
Vydáno: (2024-01-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): Part 2 Review of Experience and Evidence with SGLT-2 Inhibitors and Commentary
Autor: Soneil Guptha, Eteri Tsetskhladze
Vydáno: (2023-06-01)

Incidence of heart failure with preserved ejection fraction (HFpEF) in COPD patients during acute exacerbation in Ain Shams University Hospitals
Autor: Hossam H Sayed, a další
Vydáno: (2024-01-01)

Executive Summary from the 2023 Charleston HFpEF Conference
Autor: Sheldon E Litwin, a další
Vydáno: (2024-06-01)

Association of Plasma Myeloperoxidase with Inflammation and Diabetic status in HFpEF
Autor: Sibille Lejeune, a další
Vydáno: (2023-02-01)

Hemodynamic force analysis is not ready for clinical trials on HFpEF
Autor: Per M. Arvidsson, a další
Vydáno: (2022-03-01)

Leukocyte count and the risk of adverse outcomes in patients with HFpEF
Autor: Zhaowei Zhu, a další
Vydáno: (2021-07-01)

Phenotypic Trajectories From Acute to Stable Phase in Heart Failure With Preserved Ejection Fraction: Insights From the PURSUIT‐HFpEF Study
Autor: Yuki Matsuoka, a další
Vydáno: (2025-02-01)